JP Morgan Chase
MSGR

JP Morgan Chase’s Direxion mRNA ETF MSGR Stock Holding History

JP Morgan Chase’s Portfolio MSGR Stock Details MSGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6,729
Closed -$160K – 7195
2021
Q4 		$160K Buy
+6,729
New +$162K ﹤0.01% 5472

Other funds holding MSGR

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase's MSGR Position: Q1 2022 in Review

JP Morgan Chase sold out of Direxion mRNA ETF (MSGR) in Q1 2022, closing a stake of 6,729 shares — an estimated $160K sold.

JP Morgan Chase first reported a position in MSGR in Q4 2021 and held it in 1 quarter. The position peaked at $160K in Q4 2021. 3 funds tracked by Wall St. Rank hold MSGR as of Q1 2022.

  • JP Morgan Chase reported no remaining Direxion mRNA ETF position as of Q1 2022 after selling out during the quarter.
  • JP Morgan Chase sold 6,729 Direxion mRNA ETF shares in Q1 2022, an estimated $160K.
  • JP Morgan Chase first reported a position in Direxion mRNA ETF in Q4 2021 and held it in 1 quarter.
  • JP Morgan Chase's Direxion mRNA ETF position peaked at $160K in Q4 2021.
  • 3 funds tracked by Wall St. Rank held Direxion mRNA ETF as of Q1 2022.

Based on JP Morgan Chase's 13F filing for Q1 2022, filed 11 May 2022.